Dalzanemdor (; development code SAGE-718) is experimental drug that was previously investigated for the treatment of neurological disorders and cognitive impairment. It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition. Dalzanemdor is an analogue of the neurosteroid 24S-hydroxycholesterol.
As of 2022, dalzanemdor is in Phase II clinical trials for Alzheimer's disease, Parkinson's disease, and Huntington's disease. As of 2024, Sage Therapeutics had discontinued development of dalzanemdor following negative clinical trial results.
References
External links Dalzanemdor (SAGE-718) - Sage Therapeutics